



Dexcel Pharma and Harel Consulting to Collaborate on the Commercialization of Dexcel products in Emerging Markets

New Jersey, December 21, 2014

Dexcel Pharma ("Dexcel") and Harel Consulting, both privately held companies, initiated a collaboration to advance the registration and commercialization of Dexcel's products in Emerging Markets.

Harel Consulting, a business development consultancy firm led by Jacob Harel, has formed a unique network of pharmaceutical companies in Latin America, Eastern Europe, Middle East, Asia Pacific, Africa and Europe. This network of leading and trusted companies will provide a platform, for the registration and commercialization of Dexcel's finished drug formulations through local licensing arrangements. The first products to be licensed are Donepezil XR, Sumatriptan ODT and Levetiracetam XR for the treatment of Alzheimer, Migraine and Epilepsy respectively.

Ilan Oren, Vice President Business Development at Dexcel Pharma commented on the Agreement, saying:

"We are very pleased to have this opportunity to work with Harel Consulting. The unique international experience of the Harel Consulting team will serve our company well as we expand our reach into new markets outside the US and Europe. We believe that our unique portfolio will benefit many patients in these markets."

Jacob Harel, the founder of Harel Consulting, offered the following comment:

"Dexcel Pharma is an outstanding specialty pharmaceutical company with a highly advanced proprietary technology that successfully develops a unique, high value product portfolio. Harel Consulting has the knowledge, the experience and a wide network of contacts to support Dexcel with its international expansion strategy. We will facilitate and execute licensing arrangements with leading local and regional pharmaceutical companies in Emerging Markets. We are thrilled to have Mr. JP Gagnon, a senior pharmaceutical executive with extensive international experience, who will be leading this initiative. We look forward to a successful and productive collaboration."

These licensing arrangements, initially with Donepezil XR, Sumatriptan ODT and Levetiracetam XR, will bring more therapeutic choices to millions of patients outside the United States. Dexcel and Harel Consulting are proud to make such a contribution to the improvement of patients' health in these markets.

About Dexcel Pharma

Dexcel Pharma is a private international specialty pharmaceutical company active in >30 countries worldwide, including the US, UK and Germany. Dexcel is focused on development, manufacturing and commercialization of novel drug formulations and complex generics. Dexcel's product portfolio consists of 70 branded and generic products in over 140 dosage forms. The company was founded in 1968 and is headquartered in Israel. For more information, please visit: <http://www.dexcel.com>

About Harel Consulting

Harel Consulting is a business development consultancy firm with in-depth industry knowledge and wide network of contacts in the pharmaceutical, biotechnology, diagnostics and medical devices industries. The main focus of the company is the identification and creation of business opportunities by connecting innovative pharmaceutical companies with leading local and regional companies in international markets through long term licensing arrangements. Harel Consulting office is located in Scotch Plains, New Jersey, USA. For more information, please visit: <http://www.harelconsulting.com>